KINS is a microbiome-focused healthcare company that researches, develops, and sells products based on proprietary bacteria, including recently acquired polyamine-producing lactic acid strains. Its core offerings span consumer products (20+ SKUs) and clinic services, supported by a proprietary bacterial bank of over ~20,000 human skin specimens. The firm reports more than 100,000 cumulative users and operates two animal hospitals in Japan and one human clinic in Singapore. KINS is advancing R&D into microbiome drug seeds while preparing probiotic products and bacterial raw materials for commercial sale. The company is investing in research capability (hiring, lab expansion, equipment), PR and organizational buildout to commercialize its bacteria across B2C and B2B channels. It also plans to strengthen consumer sales via its own e-commerce and marketplace channels and to pursue joint-development and distribution partnerships with strategic corporate partners.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2024